136 related articles for article (PubMed ID: 17019708)
1. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma.
Salnikov AV; Heldin NE; Stuhr LB; Wiig H; Gerber H; Reed RK; Rubin K
Int J Cancer; 2006 Dec; 119(12):2795-802. PubMed ID: 17019708
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
[TBL] [Abstract][Full Text] [Related]
3. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
5. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
[TBL] [Abstract][Full Text] [Related]
7. [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression].
Cai YJ; Zheng DY; Luo RC; Chen JZ; Li AM; Xi JL; Ding XM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):647-9. PubMed ID: 17545079
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
[TBL] [Abstract][Full Text] [Related]
9. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947.
Libertini S; Iacuzzo I; Perruolo G; Scala S; Ieranò C; Franco R; Hallden G; Portella G
Clin Cancer Res; 2008 Oct; 14(20):6505-14. PubMed ID: 18927290
[TBL] [Abstract][Full Text] [Related]
11. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
[TBL] [Abstract][Full Text] [Related]
12. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins.
Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
Photochem Photobiol Sci; 2007 Dec; 6(12):1275-83. PubMed ID: 18046482
[TBL] [Abstract][Full Text] [Related]
13. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy.
Smith NR; Baker D; Farren M; Pommier A; Swann R; Wang X; Mistry S; McDaid K; Kendrew J; Womack C; Wedge SR; Barry ST
Clin Cancer Res; 2013 Dec; 19(24):6943-56. PubMed ID: 24030704
[TBL] [Abstract][Full Text] [Related]
14. Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model.
Bauer AJ; Patel A; Terrell R; Doniparthi K; Saji M; Ringel M; Tuttle RM; Francis GL
Ann Clin Lab Sci; 2003; 33(2):192-9. PubMed ID: 12817624
[TBL] [Abstract][Full Text] [Related]
15. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
Harada K; Supriatno ; Yoshida H; Sato M
Int J Oncol; 2005 Dec; 27(6):1489-97. PubMed ID: 16273203
[TBL] [Abstract][Full Text] [Related]
16. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
[TBL] [Abstract][Full Text] [Related]
19. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
